Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Atrium Therapeutics, Inc.NASDAQ: RNA
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) of 17.11M shares in Q1 FY2026
Q1 FY2026 weighted avg shares (diluted) was 17.11M shares.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 17.11M USD
- Year-over-year change
- —
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.11M | — |
Weighted Avg Shares (Diluted) vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Weighted Avg Shares (Diluted) figures are available to compare.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 18.62M |
| Cost of Revenue | 0 |
| Gross Profit | 18.62M |
| Gross Margin | 100.0% |
| Research & Development | 53.76M |
| Selling, General & Admin | 41.68M |
| Operating Expenses | 95.43M |
| Depreciation & Amortization | 323K |
| EBITDA | (76.5M) |
| EBITDA Margin | -410.9% |
| Operating Income | (76.81M) |
| Operating Margin | -412.6% |
| Interest Income | 0 |
| Interest Expense | 0 |
| Other Income / Expenses | (12K) |
| Income Before Tax | (76.83M) |
| Pre-Tax Margin | -412.6% |
| Income Tax Expense | (142K) |
| Net Income | (76.68M) |
| Net Margin | -411.9% |
| EPS (Basic) | (4.48) |
| EPS (Diluted) | (4.48) |
| Weighted Avg Shares | 17.11M |
| Weighted Avg Shares (Diluted) | 17.11M |
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.